This Drug Could End H.I.V. Why Hasn’t It?

<p>Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened. Guests: Dr. Grant, who has been working on H.I.V. treatment and prevention for over 30 years, and Donald G. McNeil Jr., a science and health reporter for The New York Times. For more information on today’s episode, visit <a href="https://www.nytimes.com/thedaily" target="_blank">nytimes.com/thedaily</a>. </p><p>Background reading: </p><ul><li>Gilead Sciences, the maker of Truvada, the only drug approved to prevent H.I.V. infection, will donate enough of the drug to supply 200,000 patients, but<a href="https://www.nytimes.com/2019/05/09/health/gilead-truvada-hiv-aids.html?smid=pc-thedaily" target="_blank"> critics questioned the company’s motives</a>.</li><li>The<a href="https://www.nytimes.com/2019/03/12/health/trump-hiv-aids-costs.html?smid=pc-thedaily" target="_blank"> high cost of drugs remains a major obstacle</a> to ending the AIDS epidemic.</li><li>Here’s<a href="https://www.cdc.gov/hiv/risk/prep/index.html" target="_blank"> more information about PrEP</a> from the Centers for Disease Control and Prevention website.</li></ul>